

Acquisition and disposal of own shares

Brussels (Belgium), 20 July 2022 – 20:00 (CEST) – Regulated information

Acquisition of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ("UCB" or the "Company") (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2022.

Under this program, UCB has requested a financial intermediary to repurchase up to 500 000 UCB shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 31 August 2022, effective as from 28 June 2022, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2022, UCB repurchased 89 724 UCB shares on Euronext Brussels in the period from 15 July 2022 up to and including 19 July 2022, as follows:

Date of repurchase	Number of shares	Average Price Paid	Total	Lowest Price Paid	Highest Price Paid
15 July 2022	28.000	83,24 €	2.330.683,60 €	82,20 €	84,20 €
18 July 2022	31.000	84,47 €	2.618.632,00 €	83,28 €	84,82 €
19 July 2022	30.724	84,83 €	2.606.246,25 €	84,08 €	85,20 €


As a result thereof, the Share Repurchase Program 2022 has been completed.

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
19 July 2022	16:21:53	Stock Option Plan 2018	100	€ 66,18

This press release is available on UCB SA/NV's website via the following [link](#).



UCB News

For further information, contact UCB:

Investor Relations

Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications

Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

